Study to Assess Effectiveness of Oral Atogepant in Adult Participants For Prevention of Migraine in the United Kingdom
- Sponsor
- AbbVie
- Study ID
- NCT07690215
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Study Details
Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound. The study will assess the effectiveness of atogepant for the preventive treatment of migraine in adult patients in the UK. Atogepant is an approved drug for preventive treatment of migraine in adults. Approximately 200 adult participants who are prescribed atogepant by their doctors will be enrolled in this study in the UK. Participants will receive atogepant oral tablets as prescribed by their physician. Participants will be followed for up to week 48. There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.
Key Dates
- First listed
- Jul 8, 2026
- Start date
- Sep 1, 2026
- Status verified
- Jul 2026
- Primary completion
- Mar 31, 2028
- Completion
- Mar 31, 2028
Study Design
- Enrollment
- 200 participants (estimated)
Arms
- Arm: AtogepantParticipants will receive atogepant as prescribed by their physician according to the local label.
Primary Outcome Measure
Percentage of Participants Achieving a Rating of "Much Better" or "Very Much Better" Following Atogepant Initiation As Assessed by Patient's Global Impression of Change (PGI-C) [ Time Frame: Up to approximately 12 Weeks ]
Central Contacts
- AbbVie Ltd+44 (0) 1628 561090
Find similar trials
Related Studies
- Quality Improvement and Practice Based Research in Neurology Using the EMRPHASE4 · Enrolling By Invitation · Endeavor Health · Evanston, Illinois
- Pain Biomarker StudyPHASE1 · Enrolling By Invitation · The University of Texas Health Science Center, Houston · Houston, Texas
- Objectively Diagnose and Monitor Treatment of Light SensitivityRecruiting · Randy Kardon · Iowa City, Iowa
- Mind Body Balance for Pediatric MigraineRecruiting · Children's Hospital Medical Center, Cincinnati · Cincinnati, Ohio